Healthpeak Properties Inc

Healthpeak Properties raised its full-year 2026 guidance for the second time this year, now expecting diluted earnings per share of $0.48 to $0.52, up from $0.46 to $0.50, and diluted FFO as Adjusted of $1.73 to $1.77, two cents higher at the midpoint than its prior outlook. The healthcare real estate owner signed 1.6 million square feet of new and renewal leases in the quarter, lifting outpatient medical occupancy 20 basis points to 90.7% and lab occupancy 80 basis points to 78.5%. Growth was led by Janus Living, the senior housing operator Healthpeak controls with a 73.6% stake, where revenue jumped 45% year over year to $216 million and Adjusted EBITDA rose 34% to $79 million, with same-store margins expanding 250 basis points. Healthpeak funded buybacks and debt paydown largely by selling stakes in existing buildings, including July's recapitalization that sold a 49% stake in an 86-property outpatient medical portfolio to Brookfield for roughly $1.025 billion at a 5.9% cap rate, part of $1.4 billion of proceeds generated in the quarter and through August 3. Lab same-store net operating income fell 3.2%, the only one of Healthpeak's three core businesses to shrink, holding total company-wide same-store NOI growth to 1.8%.

Healthpeak Properties raised its full-year 2026 diluted earnings per share guidance to a range of $0.48 to $0.52, following second-quarter results that showed revenue of $771.58 million and net income of $52.82 million. For the first half of 2026, net income reached $246.45 million, and the company pointed to improved profitability expectations. The raised guidance may influence how investors view the timing and resilience of earnings, especially against concerns about capital markets volatility and the funding environment for more vulnerable tenants. However, the risk that weaker biotech tenants could still pressure occupancy and rent collections remains a key short-term concern.

Brookfield Asset Management has formed a US$2.1 billion joint venture with Healthpeak covering 86 outpatient medical buildings across the United States. Healthpeak will own 51% and manage the portfolio, while Brookfield holds a 49% stake and contributes US$1.025 billion in equity. The outpatient medical real estate segment has drawn steady investor attention, and the deal extends Brookfield's footprint in income-producing healthcare assets. The partnership structure allows Brookfield to add fee-bearing exposure without taking on full operational responsibility, though it introduces third-party operating risk tied to Healthpeak's management.

Real estate stocks gained as the rotation out of technology continued, with the S&P 500 Real Estate Index Sector rising 3.94% to close at 288.04 points. The S&P 500 fell 1.96% for the week to 7,353.29, while real estate was the third-largest gaining sector behind health care and utilities. Among large-cap gainers, Healthpeak Properties led with a 10.17% weekly rise to $21.55 after JPMorgan raised its price target, and Welltower added 10.01% to $227.33. KE Holdings topped the losers, retreating 4.36% to $14.26 after President Donald Trump canceled the signing of an affordable housing bill. Hotel and resort REITs have been the biggest beneficiaries year-to-date, with the S&P 500 Hotel & Resort REITs sector adding approximately 40%.

Healthpeak Properties shares have risen 28% over the past three months, outpacing the industry's 12.4% gain. The healthcare real estate company is shifting its portfolio toward lab, outpatient medical, and life plan assets in high-barrier markets, supported by strong leasing momentum and rising occupancy. In the first quarter of 2026, lab occupancy reached 77.7%, up from 77% at year-end 2025, while outpatient medical occupancy held at 91% with 5.4% cash re-leasing spreads on renewals. Senior housing same-store cash net operating income grew 13.8% year over year, and the Janus Living platform posted 35% revenue growth and 42% adjusted EBITDA expansion. Healthpeak generated $267 million from recapitalizations, dispositions, and loan repayments in the quarter, and cash and equivalents rose to $1.17 billion, partly from the Janus Living IPO, while the company also secured a new $400 million delayed-draw term loan.

Healthpeak Properties stock has risen 12.5% over the past three months, outpacing the State Street Real Estate Select Sector SPDR ETF's 4.4% gain. On a year-to-date basis, DOC is up 21.6% compared to XLRE's 12.1% increase, and over the past 52 weeks it has returned 14.7% versus the ETF's nearly 8%. The shares surged 18.1% after first-quarter 2026 results beat expectations, with adjusted FFO of $0.45 per share and revenue of $753 million, and the company raised its full-year 2026 adjusted FFO guidance to $1.71 to $1.75 per share. Rival Welltower has lagged on a year-to-date basis with an 11.3% return but has soared 34.9% over the past 52 weeks, exceeding DOC's performance. Analysts maintain a consensus Moderate Buy rating on Healthpeak Properties with a mean price target of $21.12, representing a premium of nearly 8% to current levels.